Connect with us

Micro Cap Insider

The Hunt for Cancers Treatment: MABVAX THERAPEUTICS (OTCMKTS:MBVX)

Published

on

MABVAX THERAPEUTICS (OTCMKTS:MBVX) has had many months that Investors would love to forget as it has drifted way down after the explosive move up it made from $0.61 to $4.94 highs earlier this year.

The big story on MBVX is billionaire Dr. Phillip Frost $11.6 million investment in the Company; the man is a self-made billionaire with a keen eye on bb’s with big futures (check out COCP and DRNE) and he regularly receives national media attention from the likes of Bloomberg, CNBC and Barron’s.

MABVAX THERAPEUTICS (OTCMKTS:MBVX) is a cancer immunotherapy company focused on the development of vaccine and antibody-based therapies to address unmet medical needs in the treatment of cancer.

MabVax has the exclusive license to the therapeutic vaccines from Memorial Sloan Kettering Cancer Center. MabVax has two cancer vaccines targeting recurrent sarcoma and ovarian cancer in proof of concept Phase II multi-center clinical trials, and a vaccine targeting neuroblastoma ready for Phase II clinical development.

The Company takes a unique approach to identifying the elusive cancer antigen proteins that are effective in fighting cancer. This is the holy grail of cancer research and cancer fighting monoclonal antibodies such as the ones that MBVX is creating have been some of the most significant biotechnology products in the last 10 years generating billions of dollars in sales with products such as Herceptin, Rituxan, and Avastin.

MabVax’s lead product is a monoclonal antibody called 5B1 and all results coming back have been highly promising thus far. 5B1 was derived from a patient with stage IV breast cancer who was vaccinated in 2008 and has remained disease free for over 5 years now. MBVX is quickly moving 5B1 forward as an imaging agent, a naked antibody therapeutic, and an antibody drug conjugate.

Also important to note here is that Juno Therapeutics, an oncology giant trading at a $3.5 billion plus market valuation has been evaluating MabVax’s antibody library for potential use in novel chimeric antigen receptor (CAR) T cells.

It is easy to get excited about MBVX here; the Company has discovered a unique way to identify fully human monoclonal antibodies – the wholly grail of cancer research. Already the Company has the rights to 8 cancer vaccines.

To Find out the inside Scoop on MBVX Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

On April 6 MBVX announced it has closed on gross proceeds of approximately $11.6 million in a private placement led by OPKO Health, Inc. and Dr. Phillip Frost, CEO and Chairman of OPKO Health.

Pursuant to the Private Placement, MabVax issued a total of 15,486,001 units at $0.75 per unit for total gross proceeds of $11,614,501 before issuance costs of approximately $500,000. Each Unit consists of one share of common stock and a 30-month warrant to purchase one-half of one share of common stock (the “Warrant”).   The Warrants are exercisable at $1.50 per each whole share of common stock. Laidlaw & Company (UK) Ltd. acted as an advisor on the transaction.

Dr. Phillip Frost said “The target for MabVax’s first novel human antibody addresses important medical problems in need of better therapeutic solutions. The early data for its HuMab 5B1 antibody are encouraging and MabVax has a pipeline of dozens of novel antibody leads on its discovery platform from which it may select promising candidates to develop through clinical trials.”

On January 6 MBVX announced the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for [89] Zr-HuMab-5B1, the Company’s fully human antibody product, as a new generation PET scan cancer imaging agent. Subject to FDA authorization to proceed, MabVax plans to initiate the Phase I clinical trial in patients with pancreatic cancer in early 2016.

The Zr-HuMab-5B1 imaging agent has demonstrated high-resolution images of tumors in xenograft animal models, potentially making it an important new tool to aid in the diagnosis, monitoring and assessment of pancreatic cancer patients and an attractive companion diagnostic for the HuMab-5B1 therapeutic product. In December 2015, MabVax received the FDA’s authorization to proceed with HuMab-5B1 in a Phase I trial as a therapeutic treatment for patients with pancreatic cancer.

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $18 million market valuation MBVX does have $4.5 million in the treasury and is fully funded moving forward with the backing of Dr. Phillip Frost and his $11.6 million investment. While the stock has suffered as of late and is way down from its previous highs MBVX is an exciting story in small caps; the Company takes a unique approach to identifying the cancer antigens that are the holy grail of cancer research. Continued success of MBVX lead product 5B1 and current valuation or anywhere near it could be history. We will be updating on MBVX when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with MBVX.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in MBVX either long or short and we have not been compensated for this article.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

HUMBL, Inc. (OTCMKTS: HMBL) Stock Price is on the Rise After a Series of Developments and New Product Releases

Published

on

HUMBL, Inc. (OTCMKTS: HMBL) is a company whose stock price has a tendency to be either very stable or make massive surges and drops. The company’s stock saw a massive surge in late 2020, which continued throughout January 2021, as well. After reaching its peak near $7 in early February 2021, the price started spiraling down.

The rest of 2021 was marked by price drops, which also continued into 2022. The situation finally took a positive turn in 2023, when the price reached its bottom on February 6th, sinking to $0.0073. After that, however, it suddenly spiked up, reaching $0.0184 on February 8th.

Unfortunately, the sudden spike was followed by a sharp drop, which started immediately after the price peaked. Several support levels that the price hit along the way slightly softened the fall, such as the ones at $0.013, $0.012, and $0.010. However, the HMBL price kept going further and further down until it dropped to levels that were not seen since November 2020.

To Find out the inside Scoop on HMBL, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

The price reached its two-year low on March 16th by sinking to $0.0058. Then, suddenly, it started heading up again with a new 24% surge which took it back up to $0.009. At the time of writing, the price has corrected to $0.0081.

screenshot-www.tradingview.com-2023.03.22-11_25_09

HUMBL, Inc. (OTCMKTS: HMBL) Has been busy in 2023 so far, which is why its price has started making attempts to recover after two years of constantly spiraling down. Granted, its attempts to go up were cut short, but the company has made some major moves. One possible reason why HUMBL saw its early February spike is an announcement of a new marketing program with Emerling-Gase Motorsports and Joey Gase. The new sponsorship deal was a big move for the company, as it will be advertised during the 2023 NASCAR XFINITY race at Daytona International Speedway. However, that was not the end of it. Only two days later, new reports emerged stating that HUMBL managed to reduce its debt by $10.8 million. In addition, it announced a strategic move to simplify operations and focus on core technology via a subsidiary spin-off of Tickeri.

Three days after that, the company also launched its HUMBL mobile wallet, and a month later, HUMBL Chat audio rooms also went live. This was the company’s attempt to take the next step in delving deeper in the Web3 revolution. HUMBL previously launched a variety of Web3 products, such as HUMBL Authentics, HUMBL Chat, the mentioned HUMBL Wallet, HUMBL Tickets, HUMBL Social, HUMBL Search Engine, and HUMBL Marketplace.

For more on HMBL Subscribe Right Now!

On March 16th, reports also revealed the rollout of HUMBL’s new digital P2P and merchant payments system, launched across the Web3 platform, which allows users to make payments to verified peers using Ethereum, Polygon, or USD Coin. This is likely what caused the new price increase that HMBL has seen over the last few days, and while it was fairly short-lived, it still represented an opportunity for investors and a positive move for the company.

HUMBL, Inc. (OTCMKTS: HMBL) is a Web3 platform that features consumer and commercial divisions. The firm intends to integrate core product lines across its numerous products, including HUMBL Wallet, Search Engine, Social Media, Marketplace, Tickets, and Authentics. The company also deals in NFTs, and it even has its own metaverse. It also acts as a financial data transactions firm, with its platform connecting consumers and merchants in the digital economy. The company was quick to switch to new technologies after realizing their potential in its sector, particularly when it comes to various crypto and blockchain products mentioned above. These days, it offers its products and services to customers around the world.

The company’s CEO, Brian Foote, stated:

HUMBL is the first web3 platform in the world to deliver an integrated digital wallet, search engine, digital payments and a verified social media platform in one place. We believe that the global markets are going to move from traditional banking and middlemen services, to more inclusive digital wallets. Having verified users and merchants on HUMBL, is a natural way for customers around the world to find and send reliable peer payments and transactions between one another without a bank or middleman for verification, sending and settlement.”

HUMBL, Inc. (OTCMKTS: HMBL) is a company that has developed a wide range of Web3 services that have not yet caught the attention of the public. However, as crypto and blockchain adoption continues to expand and progress, the company’s time will come. After mass adoption hits, HUMBL will be ready to offer its products and possibly become one of the leaders in offering Web3 services that are simple to use for Web2 users. With that said, the firm might simply be ahead of the times, which would explain why its shares are currently so low. On the other hand, this represents a great opportunity for long-term investors who might conclude that HUMBL has great potential for the future. We will be updating HMBL when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with HMBL.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Pexels from Pixabay

Continue Reading

Featured

Creatd, Inc. (OTCMKTS: CRTD) Stock Price Continues to Deteriorate as the Legal Battle with The Lind Partners, LLC Continues

Published

on

Creatd, Inc. (OTCMKTS: CRTD) share value continues to drop after a brief recovery in mid-March. The firm’s stock is still not at the lowest point it has ever been, but it is not too far off at this point. The lowest that the shares have gone was $0.0457, which is the point they reached on October 11th, 2022. After that, in the final months of the previous year, the stock price shot up, reaching $1.6941 per share on November 18th.

The last time when the shares reached this height was in February 2022. However, back then, the price was rapidly spiraling down from a much higher point. Unfortunately for the company and its investors, after reaching $1.6941 in November, the share price crashed in a sharp correction, sinking to $0.50 by the end of November.

CRTD found a strong support at this level, which allowed it to bounce back up to $0.90, which is where the company encountered a strong resistance. It kept bouncing back and forth between these two levels throughout December 2022 and January 2023. However, as time passed, the fluctuations were becoming smaller, as the price seemingly started achieving greater stability. Looking back now, however, it becomes clear that the volatility may have decreased, but the overall trend became bearish somewhere in mid-January.

To Find out the inside Scoop on CRTD, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

CRTD price was dropping again, and in the second half of February, it broke the support level at $0.50, sinking to $0.16 by February 27th. After briefly recovering in early March, the price went back up to $0.3, encountering a resistance here, as well, which pushed it back down to $0.1156 this time, which was on March 14th. In the last 48 hours, the price managed to recover a bit once more, sitting at $0.15 at the time of writing.

Creatd, Inc. (OTCMKTS CRTD) stock price continues to deteriorate as the legal battle with The Lind Partners, LLC continues

Creatd, Inc. (OTCMKTS: CRTD) stock has seen a rough performance over the last year, with only a brief period of recovery in November 2022. Other than that, the last 12 months were marked by nothing but price crashes triggered by various events that followed the company. In recent months — specifically in December — the company announced an upcoming merge with Global Tech Industries, albeit without disclosing the terms of the deal. After that, reports said that Global Tech Industries had decided to bid $100 million in stock in order to acquire Creatd. Creatd even halted any discussions with other potential acquirers for 30 days as part of the LOI. At the time, its CEO and Chairman, Jeremy Frommer, said:

There are two elements to this merger, fundamental and technical. The opportunity to advance the Creatd business model and scale revenues coupled with the unique technical position we find our two public companies in, is a momentous opportunity. At the time of closing of any proposed transaction, GTII share delivery to Creatd shareholders will only occur in instances of registered ownership with the transfer agent or DTC.

For a time, everything was going well for the company until February 24th, when reports emerged that Creatd had terminated the proposed acquisition discussions with Global Tech. This was what triggered the stock crash, as many were disappointed that the deal did not succeed.

Around that time, the company was also struggling with a potential illegal naked short selling, and it launched CEOBLOC to try and fight it. One positive development at the time was the fact that CRTD became available on Upstream, which marked the third issuer to dual-list their shares on Upstream’s blockchain-powered market.

https://twitter.com/UpstreamXchange/status/1625520006770618368

However, the stock was hit with another blow a week ago when Creatd released an update regarding its legal dispute with The Lind Partners, LLC, and the company’s affiliates. The dispute concerns a convertible promissory note that amounts to $900,000.

For more on CRTD Subscribe Right Now!

According to Lind, Creatd breached certain representations and warranties in regard to the note. Lind demanded immediate repayment of the full amount, but Creatd instead decided to offer a number of alternatives. Lind refused to negotiate and Creatd filed a motion to dismiss. The company’s CEO said:

At this early stage, we are strictly trying to analyze data. There is more than enough evidence that there has been unusual trading in CRTD and it demands further investigation. To that end, we have asked legal counsel to look into filing multiple requests of trading records from market makers in CRTD stock. When and if the Company enters the discovery period in The Lind Partners, LLC case, any trading records related to The Lind Partners, LLC that were done with external broker dealers will also be analyzed.

Creatd, Inc. (OTCMKTS: CRTD) is a holding company that offers new economic opportunities to creators using partnerships and technology. The company’s goal is to empower creators and brands, and it claims that each of its companies shares a common mission — to create technologies and develop partnerships that would allow it to unlock new opportunities useful to entrepreneurs, brands, and creators, allowing them to also grow creatively, sustainably, as well as profitably.

For the moment, it appears that the situation is not the best for the company. It is in the middle of legal proceedings, its merger has failed, and its stock is one bad day away from reaching its all-time low. The chart above shows that CRTD is willing to grow and ready to jump on any opportunity, so the company still has a chance. Any piece of good news would likely send its stock to the path of recovery, which is why it is still worth keeping an eye on future developments. We will be updating on CRTD when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CRTD.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Sang Hyun Cho from Pixabay

Continue Reading

Featured

Global Tech Industries Inc (OTCMKTS: GTII) Declares War On Shorts

Published

on

Global Tech Industries Inc (OTCMKTS: GTII) has filed a lawsuit against Alpine Securities for spoofing and depressing the share price of GTII.

Global Tech Industries Inc (OTCMKTS: GTII) has filed a lawsuit against Alpine Securities for spoofing. The lawsuit claims that multiple parties were selling a significant number of shares at artificially depressed prices, which is attributed to the illegal behavior of spoofing.

According to David Reichman, CEO of GTII, the lawsuit is a significant step in the company’s efforts to protect itself and its shareholders from market manipulation. The company is represented in the case by the Christian Levine Law Group and Warshaw Burstein, LLP, two law firms that specialize in stock fraud litigation.

To Find out the inside Scoop on GTII, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

The spoofing of shares refers to a fraudulent trading practice in which traders place buy or sell orders for a security, intending to cancel them before they are executed. This behavior creates a false impression of demand, causing the market price to move in a specific direction, which benefits the trader’s position. Spoofing is a violation of federal securities laws.

The lawsuit alleges that the financial firms named in the complaint engaged in illegal behavior that allowed them to manipulate the market and benefit from GTII’s artificially depressed share prices. GTII is seeking unspecified damages and injunctive relief to prevent further market manipulation.

Wes Christian, managing partner of the Christian Levine Law Group, stated that the lawsuit is yet another example of illegal market manipulation by the defendants. He emphasized the law firm’s commitment to protecting shareholders and holding financial firms accountable for their illegal behavior.

The lawsuit is an important step for GTII in its ongoing efforts to protect its shareholders and business from illegal market activities. It remains to be seen how the lawsuit will unfold, but GTII is committed to pursuing legal action against those who engage in market manipulation that harms the company and its shareholders.

GTII has many catalysts, and the first one will be Upstream, which will open multiple avenues to throw a curveball at short sellers with special coupons and dividends. The 1-800 Law Firm deal is another catalyst that GTII is excited about. GTII expects to receive $85 million in receivables on the books, which will improve GTII’s fundamentals exponentially. This improvement in fundamentals could make the current resistance level of $2 the new floor.

Restricted dividends are another way GTII can throw a curveball at short sellers. Clean Vision’s success with restricted dividends is an example that worked in the recent past. The proof is there that it can work and is worth trying. If it is another curveball that can throw off a short seller, that’s perfect. It can’t hurt to try, especially if it is restricted, which means it will not dilute the stock for six to 12 months.

For more on GTII, Subscribe Right Now!

GTII is in an exciting time, where banks are collapsing, and the market is getting rocked. Everyone is very tense, and there is a lot of pressure. Things are not as smooth as they were a year or two ago, so this could be a really good time for GTII. Many things are happening right now, including the 1-800 deal coming in two or three weeks, the special dividends, and the lawsuit against Alpine.

When looking at the chart, GTII is testing a key level again. The $2 level has been struggling to hold above this range, but it is about to be retested again.

GTII Daily Chart

GTII Daily Chart

In conclusion, GTII is fighting back against illegal behavior and has many catalysts to help them. The current market conditions are not smooth, but GTII is in an excellent position to take advantage of this situation. With the lawsuit, the 1-800 deal, the Alpine update, and the special dividends, GTII is well-positioned to move forward.

MicroCapDaily sees GTII as one of the most exciting stories to follow. We will keep an eye on this one and push out updates as they unfold.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Hilary Clark from Pixabay

** 03/25/2023 This article has been corrected to remove potentially misleading statements. AI wrote this article from various sources on social media (Twitter, YouTube). We have no position in GTII, nor have we ever traded GTII stock. Furthermore, we were not compensated for this article on GTII, nor have we ever been paid regarding GTII, and we have no business relationship with any of the parties involved. This article aimed to generate subscribers for the Microcap Daily free newsletter.

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.